Mend – a life sciences and digital health company operating at the intersection of nutrapharma, food as medicine, and behavioral health – announced recently that it has received a round of Series A funding. The $15 million round is led by S2G Ventures, which is a leading multi-stage investment firm dedicated to backing innovative, market-based solutions to advance a more humane and healthy planet.
The company’s products solving a pressing healthcare need and demonstrable market demand for the company’s purpose has enabled mend to stand out and make an impression on investors in a difficult funding market where many startups are facing significant challenges with raising capital. And this round of funding contains a strong syndicate of backers, including S2G Ventures, iSelect Fund, Touchdown Ventures, Colorcon Ventures, Keen Growth Capital, Genhen Capital, Alumni Ventures and others.
This funding round will help mend with the execution of existing provider contracts, scale its program nationwide, reach more patients to improve perioperative and chronic care, and support key drivers of human health. And the funding will also accelerate research and development to further enhance the company’s technology platform, nutrapharma, food as medicine products, and clinical services.
Last year, mend launched a line of targeted, evidence-based nutrapharma products integrated into the mend digital behavioral health coaching platform, Upgraid by mend – which extends the care delivery model beyond the hospital setting to further recovery in the home and support patients into healthier habits that last. Upgraid by mend is known as a ‘human-first’ SMS based and AI-enabled platform that helps hospital systems to extend recovery beyond the hospital, elevating the level of care and alleviating the burden on providers. The program is already showing results with first clients moving to make mend standard of care.
With backing from those who believe in making a positive impact on the health of individuals and solving critical issues straining the healthcare industry, mend is aiming to continue making the power of healing accessible to individuals who need it.
KEY QUOTES:
“The mend products have shown to enhance patient care while reducing provider stress. S2G’s investment in mend is a reflection of our belief in the need to bridge the divide between the natural world and mainstream medicine, as well as our confidence in the company’s ability to address some of the most urgent issues within today’s healthcare system.”
— Dan Ripma, Vice President at S2G Ventures
“We aim to be an important pillar of Medicine 3.0 and are thrilled with the caliber of our investors along with the mission and values alignment. Through this funding, mend will have the opportunity to invest in transforming the patient care model to enhance healing, recovery, and introduce proactive measures to improve human health and reduce the burden of lifestyle preventable illness.”
— Eziah Syed, Co-Founder and CEO of mend
“Mend has the potential to narrow the gap between nutraceuticals and pharmaceuticals, with an emphasis on scientific validation, physician support, and patient compliance. We look forward to supporting the company, as their unique integrated platform delivers better solutions for patients, providers, and payors.”
— Kelly Boyer, Vice President of Film Coatings at Colorcon
“We are excited to be part of the mend investor group. This round will be the catalysis to move the company forward and begin to scale distribution. The impact the mend products have on preparation and recovery from surgery will be a game changer for the patient community. This investment aligns closely with our investment thesis and we feel strongly about the overall leadership at mend.”
— Michael Hennessey, CEO of GenHenn Capital Venture Fund I
